Neurocrine Biosciences, Inc.

Good day, everyone, and welcome to today's Neurocrine Biosciences Report Q1 2020 results call. At this time, all participants are in a listen-only mode. Later, you'll have the opportunity to ask questions during the question and answer session. You may register to ask a question by pressing the star and one keys on your touch-tone telephone. Excuse me. You may withdraw yourself from the queue by pressing the pound key. Please note, this call may be recorded. I'll be standing by should you need assistance. It is my pleasure to turn the program over to Kevin Gorman.

Thank you very much, and good afternoon, everyone, and thank you for joining us today. Here with me at Nurocrine is Todd Tushla, our head of investor relations, Matt Abernethy, our chief financial officer, Irie Roberts, our chief medical officer, Eric Benevich, our chief commercial officer, and Kyle Gano, our chief business development officer. Before we get started, Todd, could you read our safe harbor statement, please?

Yes, good afternoon. Certain statements made in the course of this conference call that are not historical statements may be forward-looking statements, which are subject to risks and uncertainties. Information concerning factors that could cause actual results to differ materially from those contained in or implied by the forward-looking statements is contained in the company's SEC filings, including but not limited to the company's first quarter 2020 Form 10-Q and in today's press release. copies may be obtained by visiting the investor relations page on the company's website. Any forward-looking statements are made only as of today's date, and we disclaim any obligation to update these forward-looking statements.